| |
All patients (n = 48)
|
CRT responders (n = 34, 71%)
|
CRT non-responders (n = 14, 29%)
|
P value
|
|---|
|
Age (years)
|
65 ± 10
|
64 ± 10
|
65 ± 11
|
0.893
|
|
Male, n (%)
|
30 (63%)
|
18 (53%)
|
12(86%)
|
0.033*
|
|
Ischemic etiology, n (%)
|
15(31%)
|
8 (24%)
|
7 (50%)
|
0.094
|
|
Heart rate (bpm)
|
69 ± 12
|
68 ± 12
|
71 ± 11
|
0.489
|
|
QRS duration (ms)
|
160 [160; 170]
|
160 [160; 170]
|
160 [153; 170]
|
0.649
|
|
QRS & 150 ms, n (%)
|
40 (83%)
|
29 (85%)
|
11 (79%)
|
0.676
|
|
LBBB morphology, n (%)
|
38 (79%)
|
27 (79%)
|
11 (79%)
|
1
|
|
ACE inhibitors or AR blockers, n (%)
|
46 (96%)
|
33 (97%)
|
13(93%)
|
0.503
|
|
β-blockers, n (%)
|
46 (96%)
|
33 (97%)
|
13(93%)
|
0.503
|
|
Diuretics, n (%)
|
28 (58%)
|
16 (47%)
|
12(86%)
|
0.014*
|
|
Antialdosterone, n (%)
|
18(38%)
|
14(41%)
|
4 (29%)
|
0.412
|
|
LVEF (%)
|
26 ± 6
|
28 ± 5
|
23 ± 5
|
0.002*
|
|
LVEDV (ml)
|
225 ± 85
|
209 ± 78
|
265 ± 89
|
0.037*
|
|
LVESV (ml)
|
169 ± 68
|
152 ± 57
|
207 ± 78
|
0.009*
|
|
Mitral regurgitation grade lll-IV, n (%)
|
10(21%)
|
7(21%)
|
3(21%)
|
0.0767
|
|
TAPSE (mm)
|
21 + 4
|
21 ± 4
|
20 ± 5
|
0.78
|
|
GLS (%)
|
− 8.9 ± 3.6
|
− 9.8 ± 3.4
|
− 6.5 ± 3.1
|
0.003*
|
- Data are presented as n (%), mean ± SD, median [IQR]. ACE angiotensin-converting enzyme inhibitor, AR angiotensin receptor, GLS global longitudinal strain, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, TAPSE tricuspid annular plane systolic excursion. * P value <0,05
